Lineage Cell Therapeutics Inc.

Lineage Cell Therapeutics Inc.: (LCTX) is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineage’s clinical programs are in markets with billion dollar opportunities and include three allogeneic (“off-the-shelf”) product candidates: (i) OpRegen®, a retinal pigment epithelium transplant therapy in Phase 1/2a development for the treatment of dry age-related macular degeneration, a leading cause of blindness in the developed world; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a development for the treatment of acute spinal cord injuries; and (iii) VAC, an allogeneic dendritic cell therapy platform for immuno-oncology and infectious disease, currently in clinical development for the treatment of non-small cell lung cancer. For more information, please visit http://www.lineagecell.com or follow the Company on Twitter @LineageCell.
Sector/Industry:
Healthcare/Biotechnology
Characteristics:
Based in...
US - Pacific
Clinical Stage
Phase l or ll
Disease Space
Oncology, Ophthalmology
Investement Strategy
Under the Radar
Listing
Public, USA
Market Cap
100MM - 500MM
Therapeutic Modalities
Cell Therapy
Website:
Profiles:
Address:
2173 Salk Avenue
Suite 200
Carlsbad, CA 92008
United States

Company Participants at 2nd Solebury Trout Virtual Global Healthcare Conference Series

Brian Culley
Lineage Cell Therapeutics Inc., CEO/Interim CFO
Mr. Culley joined Lineage Cell Therapeutics as CEO in September 2018. Prior to joining Lineage Cell Therapeutics, Mr. Culley served from August 2017 to September 17, 2018 as Interim Chief Executive Officer at Artemis Therapeutics, Inc., a, where he was responsible for the management of the company. Mr. Culley previously served as Chief Executive Officer of Mast Therapeutics, Inc. (“Mast”), from February 2010, and was also a member of its Board of Directors from December 2011, until Mast’s merger with Savara, Inc. in April 2017. Mr. Culley served from January 2007 to February 2010 as Mast’s Chief Business Officer and Senior Vice President, from February 2006 to January 2007 as Mast’s Senior Vice President, Business Development, and from December 2004 to February 2006 as Mast’s Vice President, Business Development. From 2002 until 2004, Mr. Culley was Director of Business Development and Marketing for Immusol, Inc. From 1999 until 2000, he worked at the University of California San Diego (UCSD) Department of Technology Transfer & Intellectual Property Services and from 1996 to 1999 he conducted drug development research for Neurocrine Biosciences, Inc. Mr. Culley has more than 25 years of business and scientific experience in the life sciences industry. He received a B.S. in biology from Boston College, a masters in biochemistry and molecular biology from the University of California, Santa Barbara, and an M.B.A. from The Johnson School of Business at Cornell University.

Top 10 Holders of Lineage Cell Therapeutics, Inc.

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
Broadwood Capital, Inc. 22.70 34,005,379 87.73 Stakes 3/11/21
Greenway Partners LP 4.56 6,827,142 17.61 Stakes 3/5/21
Vanguard Group, Inc. (Subfiler) 4.09 6,131,614 15.82 13F 12/31/20
The Vanguard Group, Inc. 3.80 5,698,909 14.70 Funds 3/31/21
Defender Capital LLC 3.30 4,950,720 12.77 13F 3/31/21
Prescott General Partners LLC 1.24 1,851,851 4.78 13F 12/31/20
BlackRock Institutional Trust Co. NA 1.03 1,535,837 3.96 13F 12/31/20
Geode Capital Management LLC 0.71 1,065,289 2.75 13F 12/31/20
ExodusPoint Capital Management LP 0.54 807,612 2.08 13F 12/31/20
Bridgeway Capital Management LLC 0.45 680,839 1.76 13F 12/31/20
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2021 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.